Jimenez Rachel B, Abdou Yara, Anderson Penny, Barry Parul, Bradfield Lisa, Bradley Julie A, Heras Lourdes D, Khan Atif, Matsen Cindy, Rabinovitch Rachel, Reyna Chantal, Salerno Kilian E, Schellhorn Sarah E, Schofield Deborah, Taparra Kekoa, Washington Iman, Wright Jean L, Zeidan Youssef H, Zellars Richard C, Horst Kathleen C
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Department of Medical Oncology, University of North Carolina, Chapel Hill, NC, USA.
Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18057-3.
This guideline provides evidence-based recommendations on the use of postmastectomy radiation therapy (PMRT) in the treatment of breast cancer. PMRT refers to the treatment of the chest wall and ipsilateral regional nodes, including at-risk axillary, supra/infraclavicular, and internal mammary nodes. Updated recommendations detail indications for PMRT in the upfront surgical setting and after neoadjuvant systemic therapy, and provide guidance on appropriate target volumes, dosing, and treatment techniques.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and the Society of Surgical Oncology convened a multidisciplinary task force to address 4 key questions focused on radiation therapy (RT) in patients with breast cancer who undergo mastectomy including (1) indications for PMRT after upfront surgery, (2) indications for PMRT after neoadjuvant systemic therapy followed by surgery, (3) appropriate PMRT treatment volumes and dose-fractionation regimens, and (4) treatment techniques. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation.
After upfront mastectomy, PMRT is indicated for most patients with node-positive breast cancer and select patients with node-negative disease. PMRT is also recommended after neoadjuvant systemic therapy, both for patients presenting with locally advanced disease and for those with residual nodal disease at the time of surgery. PMRT is conditionally recommended for patients with cT1-3N1 or cT3N0 breast cancer with pathologically negative nodes after neoadjuvant systemic therapy (ypNO). When PMRT is delivered, treatment to the ipsilateral chest wall/reconstructed breast and regional lymphatics is recommended, with moderate hypofractionation preferred, but with conventional fractionation approaches acceptable in rare cases. Computed tomography-based volumetric treatment planning with 3-dimensional conformal RT is recommended, with intensity modulated RT advised when 3-dimensional conformal RT is unable to achieve treatment goals. Deep inspiration breath hold techniques are also recommended for normal tissue sparing. For patients with skin involvement, positive superficial margins, and/or lymphovascular invasion, the use of a bolus is recommended, but the routine use of tissue-equivalent bolus is not recommended.
These evidence-based recommendations guide clinical practice on the use of PMRT in patients with breast cancer. © 2025 American Society for Radiation Oncology, American Society of Clinical Oncology and Society of Surgical Oncology. Published by Elsevier Inc on behalf of American Society for Radiation Oncology, by Wolters Kluwer Health on behalf of American Society of Clinical Oncology and by Springer Nature on behalf of Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
本指南为乳腺癌治疗中乳房切除术后放射治疗(PMRT)的使用提供基于证据的建议。PMRT是指对胸壁和同侧区域淋巴结进行治疗,包括有风险的腋窝、锁骨上/下及内乳淋巴结。更新后的建议详细说明了在初始手术情况下以及新辅助全身治疗后PMRT的适应证,并就合适的靶区体积、剂量和治疗技术提供指导。
美国放射肿瘤学会、美国临床肿瘤学会和外科肿瘤学会召集了一个多学科特别工作组,以解决4个关于接受乳房切除术的乳腺癌患者放射治疗(RT)的关键问题,包括(1)初始手术后PMRT的适应证,(2)新辅助全身治疗后再手术的PMRT适应证,(3)合适的PMRT治疗体积和剂量分割方案,以及(4)治疗技术。建议基于系统的文献综述,并使用预定义的共识建立方法以及证据质量分级和推荐强度系统制定。
在初始乳房切除术后,大多数淋巴结阳性乳腺癌患者以及部分淋巴结阴性疾病患者需要进行PMRT。新辅助全身治疗后,对于局部晚期疾病患者以及手术时仍有残留淋巴结疾病的患者,也建议进行PMRT。对于新辅助全身治疗后病理淋巴结阴性(ypN0)的cT1-3N1或cT3N0乳腺癌患者,有条件推荐进行PMRT。进行PMRT时,建议对同侧胸壁/重建乳房和区域淋巴管进行治疗,首选中等程度的大分割,但在罕见情况下传统分割方法也可接受。建议采用基于计算机断层扫描的容积治疗计划和三维适形放疗,当三维适形放疗无法实现治疗目标时,建议采用调强放疗。还建议采用深吸气屏气技术以保护正常组织。对于有皮肤受累、切缘阳性和/或淋巴管侵犯的患者,建议使用填充物,但不建议常规使用组织等效填充物。
这些基于证据的建议指导了乳腺癌患者PMRT使用的临床实践。©2025美国放射肿瘤学会、美国临床肿瘤学会和外科肿瘤学会。由爱思唯尔公司代表美国放射肿瘤学会、威科医疗代表美国临床肿瘤学会、施普林格自然集团代表外科肿瘤学会出版。保留所有权利,包括文本和数据挖掘、人工智能训练及类似技术的权利。